Kali-Chemie Pharma Gmbh

Kali-Chemic Pharma Gmbh

Insa Hell

Horst Zeugner

Wolfgang Milkowski

Hans Liepmann

Rolf Hueschens

Samuel David

Henning Heinemann

Klaus-Ullrich Wolf

Reinhard Hempel

Peter W Thies

Ulf Preuschoff

Ivan Ban

Marie-Odile Christen

Klaus-Ulrich Wolf

Herman Kraehling

Hermann Kraehling

Klau U Wolf

Pharmacologically active compounds corresponding to the general formula I: ##STR1## wherein m represents 1-4,

Phenyalkylaminoalkyl compounds and pharmaceutical compositions

Pharmacologically active compounds corresponding to the formula I ##STR1## in which n represents 2-5,

Alkylaminoalkylamine and ether compounds, processes and intermediates

The use of valepotriate hydrins in the prevention and treatment of disorders of the gastrointestinal tract is described, together with pharmaceutical compositions containing valepotriate hydrins and certain novel valepotriate hydrins per se.

Novel valepotriate hydrin containing medicines

Valepotriate hydrin containing medicines used to treat uclers and

N.sub.1 -acyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols are disclosed which possess ulcer-inhibiting activities. Further disclosed are pharmaceutical compositions which are effective in the treatment and prophylaxis of ulcers and which comprise as a pharmacologically active ulcus-inhibiting ingredient N.sub.1 -acyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable diluent. Further disclosed are processes for the preparation of the N.sub.1 -acyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols.

N.sub.1 -Acyl-N.sub.2 -phenyl-diaminopropanols and pharmaceutical

Compounds of [1,2]anellated-7-phenyl-1,4-benzodiazepines having the formula I ##STR1## wherein X is oxygen, sulfur or NR;

[1,2]Anellated-7-phenyl-1,4-benzodiazepine and pharmaceutical

N.sub.1 -benzoyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols are disclosed which exhibit a stabilizing effect on the gastric mucosa and enhance the stability and resistance of the gastic mucosa against harmful effects caused by, e.g., excessive alcohol consumption or drugs. The compounds are useful in the prophylaxis and treatment of gastritis. Further disclosed are pharmaceutical compositions which are effective in stabilizing the gastric mucosa and in the treatment and proplylaxis of gastritis and which comprise as a pharmacologically active ingredient N.sub.1 -benzoyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable diluent. Further disclosed are processes for the preparation of the N.sub.1 -benzoyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols.

N1-Benzoyl-N2-phenyldiaminopropanols and pharmaceutical compositions

N.sub.1 -acyl-N.sub.2 -phenyldiaminopropanols and pharmaceutical

Pharmaceutical compositions are disclosed, which are effective in the treatment and prophylaxis of ulcers and which comprise as a pharmacologically active ulcus-inhibiting ingredient a compound selected from the group of N.sub.1 -acyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ols, having the formula I ##STR1## wherein R.sub.1 represents 3,4-dimethoxyphenyl, 2-fluorophenyl, 2-trifluoromethylphenyl, or furyl, and pharmaceutically acceptable acid addition salts thereof, and a pharmaceutically acceptable diluent. Further disclosed is a new process for the preparation of the compounds of formula I.

Pharmaceutical compositions of N.sub.1 -acyl-N.sub.2

Growing community of inventors

Hanover, Germany

Insa Hell